SteriPack, a contract packing organisation serving the pharmaceutical industry, has announced a strategic partnership with SHL Medical (SHL), a provider of advanced drug delivery systems.
SFIO CRACHO / shutterstock.com
414162808
Partnership concept
The partnership will establish a pre-validated, highly flexible final assembly and secondary packing service at the SteriPack facility in Poland for SHL’s second-generation Molly 1.0ml autoinjector platform, adding to its small to mid-volume offering in Europe.
The collaboration between SteriPack and SHL Medical leverages the strengths of both organisations to provide high-quality final assembly and contract packing options for pharmaceutical companies seeking expert support with the complex localisation often associated with small to mid-sized volumes of targeted, self-administered drugs.
This latest alliance adds to SteriPack’s growing portfolio of global autoinjector platform partners. The partnership is testament to SteriPack’s experience devising highly tailored solutions using its specialist equipment and tooling, and the value the company places on flexibility and time-to-market for project launches.
SHL and its customers can now benefit from SteriPack’s customer-centric final assembly and secondary packing solutions offering the highest service standards, industry-leading timelines, stability, and supply chain efficiency.
Markus Puusepp, SHL Medical’s chief growth officer, said: “This partnership is a significant addition to the Molly platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward.”
John Ward, SteriPack Group’s VP Pharmaceutical Solutions, added: “SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast-moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly platform an easy decision.”
